An Early Phase 1 interventional study of Latanoprost (0.005%) in Glaucoma, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 30 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Johns Hopkins University · Early Phase 1, Interventional, and Diagnostic
Among 46 studies testing latanoprost in Glaucoma — 2 open to participants now, 2 under way, none of them phase 3. Latanoprost · Glaucoma.
Among the 46 studies testing latanoprost in Glaucoma, this one is the 32nd largest by planned enrollment of the 44 interventional ones that give a count, is the only one that started in 2026, is one of 3 in phase 1, and was the 46th registered.
1,419 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →2 of the 46 studies testing latanoprost in Glaucoma are open now, in 2 countries. Recruiting first, the newest first:
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
By country, each count listing its studies:
Latanoprost: first FDA approval 1996 (XALATAN), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 155 Glaucoma studies recruiting now, 113 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 30 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 56 across the 44 interventional studies. Of the 37 that completed or were terminated, 12 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 46 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins University is the lead sponsor of 1,815 studies on the registry; 314 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
10 studies in Glaucoma by Johns Hopkins University: 1 open now, 1 under way, none of them phase 3. Of 8 finished, 0 (0%) have results posted.
Among the 10 studies in Glaucoma by Johns Hopkins University, this one is one of 2 that started in 2026, is one of 2 in phase 1, and was the 10th registered.
Johns Hopkins University’s Glaucoma studies by the year they started, since 2009.
1 of the studies testing latanoprost in Glaucoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04957329Rigshospitalet, DenmarkEffect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 46 studies testing latanoprost in Glaucoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johns Hopkins University’s 10 in Glaucoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Persons who do not have glaucoma will have pictures taken of the optic nerve with a standard camera before and 2 weeks after starting to take a daily glaucoma eye drop to lower eye pressure. These data will be used to compare to the same procedure performed with glaucoma patients to study how glaucoma injures the eye.
The present proposal seeks to measure biomechanical strains in age-matched control subjects who do not have Open-angle Glaucoma (OAG), using the same non-invasive imaging methods as in the above programs. This is necessary as even undamaged OAG eyes may have different biomechanical properties at baseline than do non-OAG eyes. While there are some limited methods to test strains in control eyes, to compare normal to OAG responses robustly, the same methods of changing intra-ocular pressure (IOP) must be applied-namely to lower IOP by delivery of FDA-approved agent, latanoprost, as has been done in the investigator's OAG subjects. The method of measuring strain requires images taken at two different IOP levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The participants will take an approved glaucoma eye drop, latanoprost, for less than one month, with pictures of the eyes at baseline and while taking the drop.
Drug: Latanoprost (0.005%)
Participants take the eye drop daily for less than one month
Optic nerve head strain
Biomechanical strain measured by optical coherence tomography
Time frame: up to 1 month
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Mar 2028, 20 months after the start.
Of 18 phase 1 interventional studies under Glaucoma, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's planned 20 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Latanoprost